SUVOREXANT Dual Orexin OX1/OX2 Receptor Antagonist Treatment of Sleep Disorders

被引：2
|
作者：
Radl, S. [1 ]
机构：
[1] Zentiva, Prague 10237, Czech Republic
来源：
DRUGS OF THE FUTURE | 2013年 / 38卷 / 01期
关键词：
Orexin receptor antagonist; Insomnia; Sleep apnea; Suvorexant; MK-4305; PHARMACOLOGY; DISCOVERY; AMINATION;
D O I：
10.1358/dof.2013.038.01.1906425
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Suvorexant is a novel, selective, orally active dual orexin OX1 and OX2 receptor antagonist under development by Merck & Co. Phase Ill clinical trials for the treatment of insomnia have been completed and phase I clinical trials for the treatment of sleep apnea are under way. The phase III results suggested that patients taking suvorexant fell asleep faster and slept longer than those on placebo.
引用
收藏
页码：27 / 36
页数：10
相关论文
共 50 条
  • [41] Arachidonic acid release mediated by OX1 orexin receptors
    Turunen, Pauli M.
    Ekholm, Marie E.
    Somerharju, Pentti
    Kukkonen, Jyrki P.
    BRITISH JOURNAL OF PHARMACOLOGY, 2010, 159 (01) : 212 - 221
  • [42] Multiple phospholipase activation by OX1 orexin/hypocretin receptors
    L. Johansson
    M. E. Ekholm
    J. P. Kukkonen
    Cellular and Molecular Life Sciences, 2008, 65 : 1948 - 1956
  • [43] Multiple phospholipase activation by OX1 orexin/hypocretin receptors
    Johansson, L.
    Ekholm, M. E.
    Kukkonen, J. P.
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2008, 65 (12) : 1948 - 1956
  • [44] OX1 Orexin/Hypocretin Receptor Signaling through Arachidonic Acid and Endocannabinoid Release
    Turunen, Pauli M.
    Jantti, Maria H.
    Kukkonen, Jyrki P.
    MOLECULAR PHARMACOLOGY, 2012, 82 (02) : 156 - 167
  • [45] Discovery process and pharmacological characterization of a novel dual orexin 1 and orexin 2 receptor antagonist useful for treatment of sleep disorders
    Di Fabio, Romano
    Pellacani, Annalisa
    Faedo, Stefania
    Roth, Adelheid
    Piccoli, Laura
    Gerrard, Philip
    Porter, Rod A.
    Johnson, Christopher N.
    Thewlis, Kevin
    Donati, Daniele
    Stasi, Luigi
    Spada, Simone
    Stemp, Geoffrey
    Nash, David
    Branch, Clive
    Kindon, Leanda
    Massagrande, Mario
    Poffe, Alessandro
    Braggio, Simone
    Chiarparin, Elisabetta
    Marchioro, Carla
    Ratti, Emiliangelo
    Corsi, Mauro
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (18) : 5562 - 5567
  • [46] Discovery of a novel and potent dual orexin 1/orexin 2 receptor antagonist, E2006, for the treatment of sleep disorders
    Terauchi, Taro
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 249
  • [47] The orexin OX1 receptor exists predominantly as a homodimer in the basal state: potential regulation of receptor organization by both agonist and antagonist ligands
    Xu, Tian-Rui
    Ward, Richard J.
    Pediani, John D.
    Milligan, Graeme
    BIOCHEMICAL JOURNAL, 2011, 439 : 171 - 183
  • [48] Orexin receptor 2 (OX2) exhibits spatiotemporal mechanisms in its response to the endogenous ligand orexin-B
    Dale, Natasha
    Johnstone, Elizabeth
    Pfleger, Kevin
    BRITISH JOURNAL OF PHARMACOLOGY, 2023, 180 : 661 - 662
  • [49] Evidence that orexin-A evoked grooming, but not water intake, in the rat is mediated by the orexin-1 (OX1) receptor
    Duxon, M
    Stretton, J
    Porter, R
    Pilleux, JP
    Martin, JD
    Upton, N
    BRITISH JOURNAL OF PHARMACOLOGY, 2001, 134
  • [50] OX2 orexin/hypocretin receptor signal transduction in recombinant Chinese hamster ovary cells
    Kukkonen, Jyrki P.
    CELLULAR SIGNALLING, 2016, 28 (02) : 51 - 60
12345